Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx for Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis
NCT05147779Phase 1Terminated
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in Peyronie's disease, erectile dysfunction (ED) and interstitial cystitis (IC), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Sep 2021; status: terminated.
02
Drugs
AlloRx
03
Conditions
Peyronie's diseaseerectile dysfunction (ED)interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT05147779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147779.